STOCK TITAN

Option adjustments for AnaptysBio (NASDAQ: ANAB) director Renton Hollings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ANAPTYSBIO director Renton Hollings reported a series of stock option adjustments tied to a corporate separation. On April 20, 2026, he acquired multiple new options to buy AnaptysBio common stock and simultaneously disposed of corresponding older options back to the issuer. The footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into options over both companies’ shares. These are compensation and structural option changes, all held directly, and involve derivatives only rather than open-market trades in common stock.

Positive

  • None.

Negative

  • None.
Insider RENTON HOLLINGS
Role null
Type Security Shares Price Value
Disposition Stock Option (right to buy) 15,000 $0.00 --
Grant/Award Stock Option (right to buy) 15,000 $0.00 --
Disposition Stock Option (right to buy) 6,000 $0.00 --
Grant/Award Stock Option (right to buy) 6,000 $0.00 --
Disposition Stock Option (right to buy) 6,000 $0.00 --
Grant/Award Stock Option (right to buy) 6,000 $0.00 --
Disposition Stock Option (right to buy) 11,000 $0.00 --
Grant/Award Stock Option (right to buy) 11,000 $0.00 --
Disposition Stock Option (right to buy) 11,000 $0.00 --
Grant/Award Stock Option (right to buy) 11,000 $0.00 --
Disposition Stock Option (right to buy) 9,200 $0.00 --
Grant/Award Stock Option (right to buy) 9,200 $0.00 --
Disposition Stock Option (right to buy) 10,600 $0.00 --
Grant/Award Stock Option (right to buy) 10,600 $0.00 --
Disposition Stock Option (right to buy) 16,510 $0.00 --
Grant/Award Stock Option (right to buy) 16,510 $0.00 --
Disposition Stock Option (right to buy) 16,510 $0.00 --
Grant/Award Stock Option (right to buy) 16,510 $0.00 --
Disposition Stock Option (right to buy) 5,500 $0.00 --
Grant/Award Stock Option (right to buy) 5,500 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 15,000 shares (Direct, null)
Footnotes (1)
  1. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement. The stock option is fully vested and exercisable. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Option grant shares 5,500 options Grant to buy AnaptysBio common stock at $32.17, expiration 2036-01-06
Option disposition shares 5,500 options Disposition to issuer at $43.91 exercise price, expiration 2036-01-06
Option grant block 16,510 options Grant at $10.87 exercise price, expiration 2035-01-06 on AnaptysBio common stock
Matching disposition block 16,510 options Disposition to issuer at $14.83 exercise price, expiration 2035-01-06
Derivative transaction count 20 transactions All reported entries are derivative (stock option) transactions
Acquire vs dispose counts 10 acquire, 10 dispose Transaction summary shows equal counts of option grants and dispositions
Separation agreement date April 20, 2026 Effective date of Separation and Distribution Agreement with First Tracks
Separation and Distribution Agreement regulatory
"pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks"
pro rata distribution financial
"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock"
A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.
stock option financial
"The stock option is fully vested and exercisable."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vests as to 1/12 financial
"The stock option vests as to 1/12 of the total shares monthly"
disposition to issuer financial
"transaction_action": "issuer disposition""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RENTON HOLLINGS

(Last)(First)(Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$24.604/20/2026D(1)15,000 (2)02/23/2027Common Stock15,000$015,000D
Stock Option (right to buy)$18.0304/20/2026A(1)15,000 (2)02/23/2027Common Stock15,000$015,000D
Stock Option (right to buy)$104.8104/20/2026D(1)6,000 (2)02/01/2028Common Stock6,000$06,000D
Stock Option (right to buy)$76.7904/20/2026A(1)6,000 (2)02/01/2028Common Stock6,000$06,000D
Stock Option (right to buy)$68.8804/20/2026D(1)6,000 (2)02/07/2029Common Stock6,000$06,000D
Stock Option (right to buy)$50.4704/20/2026A(1)6,000 (2)02/07/2029Common Stock6,000$06,000D
Stock Option (right to buy)$16.5604/20/2026D(1)11,000 (2)02/11/2030Common Stock11,000$011,000D
Stock Option (right to buy)$12.1404/20/2026A(1)11,000 (2)02/11/2030Common Stock11,000$011,000D
Stock Option (right to buy)$29.704/20/2026D(1)11,000 (2)02/09/2031Common Stock11,000$011,000D
Stock Option (right to buy)$21.7604/20/2026A(1)11,000 (2)02/09/2031Common Stock11,000$011,000D
Stock Option (right to buy)$30.4404/20/2026D(1)9,200 (2)02/09/2032Common Stock9,200$09,200D
Stock Option (right to buy)$22.1304/20/2026A(1)9,200 (2)02/09/2032Common Stock9,200$09,200D
Stock Option (right to buy)$23.2304/20/2026D(1)10,600 (2)01/05/2033Common Stock10,600$010,600D
Stock Option (right to buy)$17.0204/20/2026A(1)10,600 (2)01/05/2033Common Stock10,600$010,600D
Stock Option (right to buy)$21.1904/20/2026D(1)16,510 (2)01/02/2034Common Stock16,510$016,510D
Stock Option (right to buy)$15.5304/20/2026A(1)16,510 (2)01/02/2034Common Stock16,510$016,510D
Stock Option (right to buy)$14.8304/20/2026D(1)16,510 (2)01/06/2035Common Stock16,510$016,510D
Stock Option (right to buy)$10.8704/20/2026A(1)16,510 (2)01/06/2035Common Stock16,510$016,510D
Stock Option (right to buy)$43.9104/20/2026D(1)5,500 (3)01/06/2036Common Stock5,500$05,500D
Stock Option (right to buy)$32.1704/20/2026A(1)5,500 (3)01/06/2036Common Stock5,500$05,500D
Explanation of Responses:
1. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
2. The stock option is fully vested and exercisable.
3. The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Dan Faga, Attorney-in-Fact04/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What does the Renton Hollings Form 4 for ANAPTYSBIO (ANAB) report?

The Form 4 shows director Renton Hollings reported multiple stock option adjustments on April 20, 2026. He acquired new options and disposed of corresponding prior options to the issuer, reflecting structural changes rather than open-market trading in AnaptysBio common shares.

Why were ANAPTYSBIO options adjusted under the Separation and Distribution Agreement?

Footnotes state each existing AnaptysBio option was adjusted after a pro rata distribution under an April 20, 2026 Separation and Distribution Agreement with First Tracks. Each outstanding option became two options, one over First Tracks shares and one over AnaptysBio shares, changing Hollings’ option profile.

Did Renton Hollings buy or sell ANAPTYSBIO common stock in this Form 4?

The reported transactions all involve stock options, not open-market trades in common stock. Codes show grants or awards (acquisitions) and dispositions to the issuer, indicating compensation and structural option changes rather than direct buying or selling of AnaptysBio shares in the market.

How many derivative transactions are reported in the ANAB Form 4 for Hollings?

The transaction summary lists 20 derivative transactions, all involving stock options. There are 10 acquisitions classified as grants or awards and 10 dispositions back to the issuer, leaving the net reported buy-sell share count neutral according to the Form 4 summary data.

What are examples of option strike prices in Renton Hollings’ ANAPTYSBIO Form 4?

Examples include options to acquire 16,510 shares of AnaptysBio common stock at a $10.87 exercise price and others at $32.17 and $21.76. Matching option blocks at higher exercise prices were disposed to the issuer as part of the same adjustment process.

How do the vesting terms work for Hollings’ ANAPTYSBIO options in this filing?

A footnote explains at least one option grant vests 1/12 of the total shares monthly, starting February 6, 2026. Vesting continues until fully vested, provided Renton Hollings continues to provide service to AnaptysBio on each monthly vesting date.